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Abstract
Antemortem tau positron emission tomography imaging suggests elevated tau
pathology in autosomal dominant versus late-onset Alzheimer’s disease at
equivalent clinical stages, but does not implicate the specific tau pathologies
responsible. Here we made stereological measurements of tau neurofibrillary
tangles, neuritic plaques, and neuropil threads and found compared to late-on-
set Alzheimer’s disease, autosomal dominant Alzheimer’s disease showed even
greater tangle and thread burdens. Regional tau burden resembled that observed
in tau imaging of a separate cohort at earlier clinical stages. Finally, our results
suggest tau imaging measures total tau burden in Alzheimer’s disease, com-
posed predominantly of tangle and thread pathology.
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Introduction
Antemortem tau positron emission tomography (PET)
imaging suggests elevated tau pathology in autosomal domi-
nant (ADAD) versus late-onset Alzheimer’s disease (LOAD)
at equivalent clinical stages. Compared to LOAD, ADAD has
shown elevated 18F-flortaucipir1 radioligand binding in pre-
frontal, premotor, and inferior parietal cortices,2 as well as
precuneus and lateral parietal cortices.3 However, PET imag-
ing does not implicate specific tau pathologies responsible.
Previous work quantitatively comparing AD tau pathology
with PET imaging has typically been performed in a single
individual,4,5 and it is not known whether these results gen-
eralize, given the disease heterogeneity of both ADAD6 and
LOAD7. To investigate which tau pathologies contribute to
elevated 18F-flortaucipir binding in ADAD versus LOAD
cohorts, we made stereological measurements of three major
features of AD tau pathology: neurofibrillary tangles, neuritic
plaques, and neuropil threads.
Methods
Protocols for the study have received prior approval by
the local Institutional Review Board of each Dominantly
Inherited Alzheimer Network site. Informed consent was
obtained from each participant.
Cases selected for postmortem study were participants
in the Dominantly Inherited Alzheimer Network (n = 7)
or in studies directed by the Knight Alzheimer Disease
Research Center (n = 10) (Table 1). These individuals
met the inclusion criteria of high AD neuropathological
change8 without comorbid neurodegenerative or vascular
disease.
Neuropathological assessment of cases involved expert
evaluation of histology slides representing 16 brain areas
from the left side of each brain.9 Stereology focused on
tissues sampled in the coronal plane, including the frontal
lobe (middle frontal gyrus), temporal lobe (superior and
middle temporal gyri), parietal lobe (inferior parietal lobe
including angular gyrus), occipital lobe (calcarine sulcus
and peristriate cortex), parahippocampal gyrus, and hip-
pocampal subfield CA1 (both sampled at the level of the
lateral geniculate nucleus). From these regions, stereologi-
cal measurements of PHF-1 (a gift from Dr. Peter Davies)
immunostained tangles, plaques, and threads were made
using the Area Fraction Fractionator probe in Stereo
Investigator 10 (MBF Bioscience, Williston, VT, USA).
In a separate cohort (ADAD n = 14, LOAD n = 35),
antemortem 18F-flortaucipir PET was quantified using
regional standardized uptake value ratios (SUVRs).10
These individuals met the inclusion criteria of having a
Clinical Dementia Rating (CDR)11 greater than 0; indi-
viduals with LOAD additionally had positive amyloid
PET imaging.12 Regional SUVRs of interest were defined
by FreeSurfer13 regions best corresponding to neu-
ropathology regions: caudal middle frontal cortex, middle
temporal cortex, inferior parietal cortex, pericalcarine cor-
tex, parahippocampal cortex, and hippocampus.
Regional differences across and within ADAD and
LOAD in neuropathology and imaging were assessed
using the Kruskal–Wallis test. Post hoc Wilcoxon rank-
sum tests were performed with Bonferroni–Holm multiple
comparisons correction to assess which regions showed
elevated tau burden in ADAD versus LOAD.
Results
Tangle, plaque, thread burden, and SUVR showed statisti-
cally significant regional differences across ADAD and
LOAD. Only tangle burden and SUVR showed significant
regional differences within ADAD and LOAD as well
(Fig. 1).
Compared to LOAD, tangle burden in ADAD was sig-
nificantly elevated outside the temporal lobe. Patterns of
regional tangle burden resembled those of regional
SUVRs. However, while CA1 is highest in median tangle
burden, the hippocampus has only the third and fourth
highest median SUVR in ADAD and LOAD, respectively
(Fig. 1C&F).
Neuritic plaque burden was elevated in ADAD, but no
post hoc test reached statistical significance after multiple
comparisons correction. Thread burden was elevated out-
side CA1 (Fig. 1B&D).
Discussion
Antemortem tau PET SUVRs and postmortem tangle bur-
den in frontal and parietal regions were elevated in
ADAD versus LOAD. This concordance appears robust at
the group level, even though antemortem imaging and
postmortem neuropathology were assessed in different
cohorts, roughly representing early and late clinical stages
of AD, respectively (Table 1). Additionally, the ADAD
neuropathology cohort demonstrates an earlier age of
onset than the ADAD imaging cohort, suggesting more
aggressive forms of AD pathology in the former.
Given differences in clinical stage and age of onset, it is
not surprising there are also discordant findings. First, in
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ADAD, tangle burden is elevated in the occipital lobe rel-
ative to LOAD, but SUVR is not. Second, medial tempo-
ral lobe regions show some of the highest regional tangle
burden in the neuropathology, but not imaging, cohort.
There are several potential explanations. First, tau burden
may be particularly modest in the medial temporal lobe
at early symptomatic stages of AD, but increase substan-
tially by end stage. Second, PET imaging may have diffi-
culty resolving the tau burden of small brain structures
compared to histopathological assessment. Finally, some
individuals in the imaging cohort may have subtle neu-
ropathological comorbidities that contribute to cognitive
impairment, qualifying an amyloid PET positive case with
low AD neuropathological change (transentorhinal versus
limbic stages of tau pathology) for inclusion in this study.
More discordances between imaging and neuropathol-
ogy come from patterns of regional neuritic plaque and
thread burden. Plaque burden was elevated in ADAD,
though no post hoc test reached statistical significance,
and thread burden was elevated outside CA1. Ringman
et al.14 found statistically significant elevation of plaque
burden in a larger cohort (ADAD n = 60, LOAD
n = 120), but used a semi-quantitative global score for
each individual. We could not find any published studies
comparing levels of neuropil threads between ADAD and
LOAD. We also attribute these discordant findings to dif-
ferences in clinical stage between neuropathology and
imaging cohorts.
Comparing frontal, temporal, and parietal lobe values
suggests tau PET SUVRs may correspond best to total tau
burden (summed contributions from tangles, plaques,
and threads). Similarly, Smith et al.4 found regional
SUVRs correlated best with regional total tau burdens in
a single individual with ADAD. However, that study also
found threads outnumbered tangles in every studied brain
region; we found no significant statistical dominance of
thread over tangle burden in any region in either ADAD
or LOAD.
Given our findings, we can make two conservative
claims. First, although tau PET did not assess individuals
in late stages of AD, and our neuropathologic assessments
focused on very late stages, the regional pattern of ele-
vated tau radioligand binding is largely concordant with
the regional pattern of elevated postmortem total tau bur-
den in ADAD versus LOAD. This suggests regional differ-
ences in tau pathology between ADAD and LOAD are
consistent throughout their symptomatic stages. We pro-
pose that tau PET did not identify the relatively high tau
burdens seen in the neuropathological assessment of CA1
and the parahippocampal gyrus because, at the level of
the lateral geniculate nucleus, these areas develop far
more robust tauopathy only in late stages of AD neu-
ropathological change,15,16 that are more likely to be asso-
ciated with a terminal Clinical Dementia Rating of 3 than
0.5 or 1. In contrast, the entire hippocampus was assessed
in tau PET imaging, which may explain some of the dis-
cordance in this comparison.
Second, like tangle burden, thread burden is elevated in
ADAD versus LOAD, and across more brain regions,
while plaque burden is elevated to a lesser extent. A possi-
ble explanation for greater tangle and thread burden in
ADAD than LOAD might be that LOAD is often a multi-
factorial process, with cerebral small vessel disease, TDP-
43, and other co-pathologies contributing to the clinico-
pathological phenotype such that less AD neuropathologic
change is needed to reach similar states of dementia
severity. That said, enhancement of tangle and thread
burden in ADAD compared to LOAD without an equally
Table 1. Cohort demographics.
Neuropathology cohort Imaging cohort
LOAD ADAD LOAD ADAD
Number 10 7 35 14
Age at visit, years (SD) 74.9 (6.75) 50 (12.5)
Age at onset, years (SD) 63.1 (9.83) 38.4 (4.65) 48.3 (0.83)1
Age at death, years (SD) 73.4 (8.29) 44.9 (7.47)
Female (%) 6 (60%) 4 (57.1%) 19 (54.3%) 8 (57.1%)
MMSE at visit, score (SD) 25.3 (3.88) 21.9 (6.40)
CDR at visit, score (0/0.5/1/2/3) 0.657 (0/26/8/1/0) 0.714 (0/12/1/0/1)
CDR at death, score (0/0.5/1/2/3) 2.75 (0/0/1/0/7) 3 (0/0/0/0/6)
APOE e4 (%) 7/9 (77.8%) 1/7 (14.3%) 22/34 (64.7%) 4/14 (28.6%)
Family Mutation APP/PSEN1/PSEN2 0/7/0 1/12/1
Ab plaque score (A0/1/2/3) 3 (0/0/0/10) 3 (0/0/0/7)
NFT stage (B0/1/2/3) 3 (0/0/0/10) 3 (0/0/0/7)
Neuritic plaque score (C0/1/2/3) 2.9 (0/0/1/9) 3 (0/0/0/7)
1Includes estimated age at onset using expected years to symptom onset (EYO).
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strong enhancement of plaque burden may seem unusual.
One explanation suggests tangles and threads are patho-
physiologically closely linked, with tangles appearing first,
and threads reflecting more severe saturation of neuronal
processes by abnormal tau, whereas neuritic plaques
develop later,16 and reflect more focal disturbances that
leave remaining neuronal cytosol unperturbed. Another
explanation: on sections immunostained for tau, within
areas of very dense threads, plaques are occasionally diffi-
cult to discern, and might be undercounted.
We note the limitations to this study. First, no individ-
uals in our neuropathology cohort had undergone
antemortem tau PET, precluding direct imaging-neu-
ropathology comparisons. Second, regions included in
the neuropathology portion of this study were limited in
number and not perfectly correspondent to those from
tau PET. Third, most ADAD individuals who came to
autopsy were at the end stage of disease. Finally, there is
a difference in age of AD symptom onset between the
imaging and neuropathology cohorts. Earlier ages of
onset appear to be correlated with higher cortical tau
PET signal17–19 and thus there may be a mixed contribu-
tion of mutation and early age of onset to the tau PET
imaging of the ADAD cohort. From the current study,
the tau pathologies responsible for differences observed in
tau PET between ADAD versus LOAD were revealed to
be predominantly neurofibrillary tangles and neuropil
threads. However, our current findings cannot address
how temporal progression of tau pathology in ADAD dif-
fers from that in LOAD (hypothesized to begin in the
brain stem20,21 and suspected to share early-stage distri-
bution in the medial temporal lobe with primary age-re-
lated tauopathy22). Future work can investigate the
temporal progression of AD tau pathology more broadly
by studying the relationship between earlier/later ages of
AD symptom onset and tau pathology. One possibility is
to introduce an early-onset sporadic AD cohort to help
disentangle the contributions of an earlier age of onset
Figure 1. (A) Exemplar PHF-1 immunostained neuropil threads (NT), neurofibrillary tangles (NFT), and neuritic plaques (NP). (B) Regional NT
burden in the frontal lobe (FL), temporal lobe (TL), parietal lobe (PL), occipital lobe (OL), parahippocampal gyrus (PHG), and hippocampal subfield
CA1 in ADAD and LOAD. (C) Regional NFT burden. (D) Regional NP burden. (E) Regional total tau (NT + NFT+NP) burden. (F) Regional 18F-
flortaucipir PET imaging SUVRs. Asterisks denote P-values < 0.05 (*), 0.01 (**), and 0.001 (***) for regionwise Wilcoxon rank-sum tests between
ADAD and LOAD. Only area under the curves (AUCs, the probability that a randomly selected ADAD individual has a higher regional tau burden
than a randomly selected LOAD individual) that are statistically significant after Bonferroni–Holm multiple comparisons correction are displayed.
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form the specific mutations that define the ADAD
cohort.
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